Longer term (> 1 year after disease onset) coronary morbidity (non‐aneurysmal) · children diagnosed with Kawasaki disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain resolution · patients with sore throat
Corticosteroids leads to higher complete resolution of pain at 24 hours compared with placebo (high certainty).
2 findings from 1 review
Time to initial pain relief (minutes) · patients with sore throat
1 finding from 1 review
Mean time to resolution of pain · patients with sore throat
1 finding from 1 review
Absolute reduction in pain measured by VAS · patients with sore throat
1 finding from 1 review
Adverse events · patients with sore throat
Corticosteroids showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · patients with sore throat
Corticosteroids showed no clear difference in recurrence/relapse rates compared with placebo (moderate certainty).
1 finding from 1 review
Days missed from work or school · patients with sore throat
1 finding from 1 review
28‐Day all‐cause mortalitya · children and adults with sepsis
Corticosteroids probably leads to lower 28‐Day all‐cause mortalitya compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Long‐term mortalityc · children and adults with sepsis
Corticosteroids showed no clear difference in long‐term mortalityc compared with placebo or usual care (low certainty).
1 finding from 1 review
Hospital mortality · children and adults with sepsis
Corticosteroids probably leads to lower hospital mortality compared with placebo or usual care (moderate certainty).
1 finding from 1 review
ICU length of stay (general intensive care patients) · children and adults with sepsis
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · children and adults with sepsis
1 finding from 1 review
Number of participants with adverse events ‐ superinfection (up to longest · children and adults with sepsis
Corticosteroids showed no clear difference in number of participants with adverse events ‐ superinfection (up to… compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis
Corticosteroids leads to higher number of participants with adverse events ‐ muscle weakness (up to… compared with placebo or usual care (high certainty).
1 finding from 1 review
Mortality ‐ adults · people with community‐acquired pneumonia
Corticosteroids probably leads to lower mortality ‐ adults compared with control (moderate certainty).
1 finding from 1 review
Mortality ‐ adults ‐ severe CAP · people with community‐acquired pneumonia
Corticosteroids probably leads to lower mortality ‐ adults ‐ severe CAP compared with control (moderate certainty).
1 finding from 1 review
Mortality ‐ adults ‐ non‐severe CAP · people with community‐acquired pneumonia
Corticosteroids showed no clear difference in mortality ‐ adults ‐ non‐severe CAP compared with control (moderate certainty).
1 finding from 1 review
Early clinical failure ‐ adults · people with community‐acquired pneumonia
Corticosteroids probably leads to lower early clinical failure ‐ adults compared with control (moderate certainty).
1 finding from 1 review
Early clinical failure ‐ adults ‐ severe CAP · people with community‐acquired pneumonia
Corticosteroids leads to lower early clinical failure ‐ adults ‐ severe CAP compared with control (high certainty).
1 finding from 1 review